Completed PHASE4 INTERVENTIONAL 2-arm NCT00835159

Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial

Sponsor: NYU Langone Health

Conditions Delirium Postoperative Cognitive Dysfunction

Interventions Placebo Patch Rivastigmine Patch

Updated 10 times since 2017 Last updated: Jan 26, 2015 Started: Dec 31, 2008 Primary completion: Jul 31, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Delirium and Postoperative Cognitive Dysfunction, this trial is completed. The trial is conducted by NYU Langone Health and has accumulated 10 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Dec 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 5 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2019 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Jun 2019 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NYU Langone Health
Novartis

Data source: NYU Langone Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States